Working... Menu

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03324776
Recruitment Status : Recruiting
First Posted : October 30, 2017
Last Update Posted : March 13, 2019
Mannkind Corporation
Information provided by (Responsible Party):
Philip Levin, Model Clinical Research LLC

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 15, 2020
  Estimated Study Completion Date : September 15, 2020